bladder cancer

AUA 2014: Studies shine light on new PCa tests, TRT safetyIn our “Best of AUA” report, Urology Times’ editors and writers present the AUA annual meeting’s take-home messages in 15 therapeutic areas.
Best of AUA 2014: Outcomes AnalysisJesse D. Sammon, DO, presents the take home messages on outcomes analysis from the AUA annual meeting in Orlando, FL.
Best of AUA 2014: Bladder CancerWassim Kassouf, MD, CM, presents the take home messages on bladder cancer from the AUA annual meeting in Orlando, FL.
Best of AUA 2014: Basic Science ResearchK.C. Balaji, MD, presents the take home messages on basic science research from the AUA annual meeting in Orlando, FL.
[BLOG] Blessings in disguise Should formularies welcome premium-priced bladder cancer drugs?The management of bladder cancer represents one of the most costly and underestimated challenges in the oncology spectrum. Despite having the 6th highest incidence of any cancer in the United States, high recurrence rates and the need to constantly monitor patients act as the primary drivers for the high expenditures associated with the disease.
Analysis IDs trends in post-cystectomy readmissionsContinent urinary diversion and postoperative complications were found to be independent predictors of hospital readmission following radical cystectomy in an analysis from the University of Wisconsin, Madison.
Urology Product Preview May 2014Drugs and devices in the pipeline from MEI Pharma, Bayer HealthCare, Merck, Pfizer, and Minomic International.
Growth factor inhibition shows promise in bladder CaPreliminary studies suggest that inhibition of fibroblast growth factor receptors (FGFR) 1, 2, 3, and 4 may be a promising approach for the treatment of bladder cancers and other cancers that harbor FGFR alterations.
Gene set breaks high-grade bladder cancer into two subtypesResearchers at the University of North Carolina School of Medicine, Chapel Hill, have identified a discrete set of genes that segregate high-grade bladder cancer into two distinct subtypes—basal-like and luminal—each of which appears to have its own molecular characteristics and outcome. The authors also found that the two subtypes share many of the characteristics seen in basal and luminal breast cancer subtypes, a discovery with clinical implications.
Bladder cancer study identifies therapeutic targetsA comprehensive molecular characterization of muscle-invasive urothelial bladder carcinoma suggests multiple opportunities for therapeutic intervention.